E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis
- PMID: 34239062
- DOI: 10.1038/s41556-021-00708-8
E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis
Abstract
Inflammatory bowel diseases present with elevated levels of intestinal epithelial cell (IEC) death, which compromises the gut barrier, activating immune cells and triggering more IEC death. The endogenous signals that prevent IEC death and break this vicious cycle, allowing resolution of intestinal inflammation, remain largely unknown. Here we show that prostaglandin E2 signalling via the E-type prostanoid receptor 4 (EP4) on IECs represses epithelial necroptosis and induces resolution of colitis. We found that EP4 expression correlates with an improved IBD outcome and that EP4 activation induces a transcriptional signature consistent with resolution of intestinal inflammation. We further show that dysregulated necroptosis prevents resolution, and EP4 agonism suppresses necroptosis in human and mouse IECs. Mechanistically, EP4 signalling on IECs converges on receptor-interacting protein kinase 1 to suppress tumour necrosis factor-induced activation and membrane translocation of the necroptosis effector mixed-lineage kinase domain-like pseudokinase. In summary, our study indicates that EP4 promotes the resolution of colitis by suppressing IEC necroptosis.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Comment in
-
Prostanoids put a brake on necroptosis in IBD.Nat Cell Biol. 2021 Jul;23(7):680-681. doi: 10.1038/s41556-021-00717-7. Nat Cell Biol. 2021. PMID: 34239061 No abstract available.
Similar articles
-
Prostaglandin E receptor EP4 stimulates lymphangiogenesis to promote mucosal healing during DSS-induced colitis.Biomed Pharmacother. 2020 Aug;128:110264. doi: 10.1016/j.biopha.2020.110264. Epub 2020 May 22. Biomed Pharmacother. 2020. PMID: 32447215
-
A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis.Clin Sci (Lond). 2019 Apr 16;133(8):919-932. doi: 10.1042/CS20181081. Print 2019 Apr 30. Clin Sci (Lond). 2019. PMID: 30944150
-
Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.J Pharmacol Exp Ther. 2010 Dec;335(3):546-52. doi: 10.1124/jpet.110.173252. Epub 2010 Sep 10. J Pharmacol Exp Ther. 2010. PMID: 20833794
-
Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut.Front Immunol. 2019 May 20;10:1094. doi: 10.3389/fimmu.2019.01094. eCollection 2019. Front Immunol. 2019. PMID: 31164887 Free PMC article. Review.
-
Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases.J Cardiovasc Pharmacol. 2012 Feb;59(2):116-23. doi: 10.1097/FJC.0b013e3182244a12. J Cardiovasc Pharmacol. 2012. PMID: 21697732 Free PMC article. Review.
Cited by
-
EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death.Nat Commun. 2024 Feb 12;15(1):1282. doi: 10.1038/s41467-024-45539-x. Nat Commun. 2024. PMID: 38346956 Free PMC article.
-
Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment.Nat Commun. 2024 Jan 11;15(1):451. doi: 10.1038/s41467-024-44689-2. Nat Commun. 2024. PMID: 38200005 Free PMC article.
-
IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.Gut. 2024 Jan 5;73(2):282-297. doi: 10.1136/gutjnl-2023-329628. Gut. 2024. PMID: 37884352 Free PMC article.
-
Single hormone or synthetic agonist induces Gs/Gi coupling selectivity of EP receptors via distinct binding modes and propagating paths.Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2216329120. doi: 10.1073/pnas.2216329120. Epub 2023 Jul 21. Proc Natl Acad Sci U S A. 2023. PMID: 37478163 Free PMC article.
-
Breaking bad: necroptosis in the pathogenesis of gastrointestinal diseases.Front Immunol. 2023 Jun 20;14:1203903. doi: 10.3389/fimmu.2023.1203903. eCollection 2023. Front Immunol. 2023. PMID: 37409125 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
